beta Amyloid Antikörper (C-Term, N-Term)

Produktnummer ABIN126727

Produktdetails anti-beta Amyloid Antikörper

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Bindungsspezifität: AA 1-43, C-Term, N-Term

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser beta Amyloid Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Spezifität: This antibody specifically interacts with the C-Terminus of b-Amyloid (1-43) and does not cross react with b-Amyloid (1-40) or (1-42), respectively.

Aufreinigung: Subsequent thiophilic adsorption and size exclusion chromatography

Immunogen: C-terminal peptide conjugated to KLH.

Klon: 6G12

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Western blot: 0.5 μg/mL for HRPO/ECL detection. Immunocytochemistry: 0.1-1 μg/mL. ELISA: 0.05 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Rekonstitution: Restore with 1 mL H2O (15 min, RT)

Buffer: 1 mL2xPBS containing 0.09 % Sodium Azide as preservative and PEG and Sucrose as stabilizer

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: For long-term storage, freeze lyophilizate upon arrival (-20 °C). Upon reconstitution,aliquote and freeze in liquid nitrogen. reconstituted antibody can be stored frozen at -80 °Cup to 1 year. Thaw aliquots at 37 °C. Thawed aliquots may be stored at 2-8 °C up to 3 months. Avoid repeated freeze-thaw cycles.
Shelf life: one year from despatch.

Haltbarkeit: 12 months

Details zu beta Amyloid

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Andere Bezeichnung: Amyloid beta (Abeta Produkte)

Hintergrund: The beta-amyloid peptide (beta A4), proteolytically released from the amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease. Cleavage of APP by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).Synonyms: Amyloid beta peptide

Pathways: Inflammasome